Legend Biotech (LEGN)
21.52
-0.23 (1.06%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
September 4, 2026 6:44 AM - StreetInsider
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
September 1, 2026 9:07 AM - StreetInsider
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
September 1, 2026 8:00 AM - StreetInsider
Parabilis Medicines adds former J&J oncology executive to board
August 25, 2026 7:01 AM - StreetInsider
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
August 25, 2026 7:00 AM - Globe NewsWire
Form 4 Legend Biotech Corp For: Aug 14 Filed by: BASH ALAN
August 18, 2026 4:16 PM - SEC Filing
Form 6-K Legend Biotech Corp For: Aug 18
August 18, 2026 4:01 PM - SEC Filing
Legend Biotech Corp. (LEGN) PT Lowered to $24 at TD Cowen
August 12, 2026 9:43 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Raised to $49 at Morgan Stanley
August 12, 2026 8:12 AM - StreetInsider
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
August 12, 2026 8:00 AM - Globe NewsWire
Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
August 12, 2026 6:10 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Lowered to $78 at Barclays
August 12, 2026 5:26 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jun 30
August 11, 2026 7:54 AM - SEC Filing
Legend Biotech (LEGN) Tops Q2 EPS by 9c
August 11, 2026 7:16 AM - StreetInsider
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
August 11, 2026 7:00 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Aug 06
August 6, 2026 4:07 PM - SEC Filing
Form SCHEDULE 13G/A Legend Biotech Corp Filed by: FMR LLC
August 6, 2026 10:32 AM - SEC Filing
Form 3 Legend Biotech Corp For: Jul 24 Filed by: BASH ALAN
August 3, 2026 5:02 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
July 30, 2026 6:51 AM - StreetInsider
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
July 28, 2026 8:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
July 28, 2026 6:42 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Lowered to $58 at Raymond James
July 27, 2026 9:55 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Lowered to $59 at RBC Capital
July 27, 2026 7:21 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jul 27
July 27, 2026 6:03 AM - SEC Filing
Legend Biotech names interim CEO after Ying Huang steps down
July 27, 2026 6:00 AM - StreetInsider
Legend Biotech Announces CEO Transition
July 27, 2026 6:00 AM - StreetInsider
UBS Downgrades Legend Biotech Corp. (LEGN) to Neutral
July 24, 2026 4:30 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
July 16, 2026 6:48 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jul 15
July 15, 2026 7:30 AM - SEC Filing
JPMorgan Resumes Legend Biotech Corp. (LEGN) at Neutral
July 13, 2026 3:13 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Lowered to $63 at RBC Capital
July 7, 2026 8:00 AM - StreetInsider
Form 4 Legend Biotech Corp For: Jun 30 Filed by: Casey Patrick John
July 2, 2026 4:06 PM - SEC Filing
Form 4 Legend Biotech Corp For: Jun 30 Filed by: Huang Ying
July 2, 2026 4:06 PM - SEC Filing
Form 144 Legend Biotech Corp Filed by: Casey Patrick John
June 30, 2026 10:47 AM - SEC Filing
Form 4 Legend Biotech Corp For: Jun 25 Filed by: Huang Ying
June 29, 2026 9:53 PM - SEC Filing
Form 144 Legend Biotech Corp Filed by: Huang Ying
June 26, 2026 3:23 PM - SEC Filing
Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board
June 23, 2026 8:00 AM - StreetInsider
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026 8:00 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jun 22
June 22, 2026 4:20 PM - SEC Filing
Form 424B5 Legend Biotech Corp
June 18, 2026 4:37 PM - SEC Filing
Legend Biotech prices $226 million public offering of ADS shares
June 17, 2026 9:22 PM - StreetInsider
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026 9:21 PM - Globe NewsWire
Form 424B5 Legend Biotech Corp
June 17, 2026 4:50 PM - SEC Filing
Form F-6EF Legend Biotech Corp Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary
June 17, 2026 4:43 PM - SEC Filing
Legend Biotech launches $225 million ADS public offering
June 17, 2026 4:29 PM - StreetInsider
Legend Biotech Corporation Announces Proposed Public OfferingÂ
June 17, 2026 4:29 PM - Globe NewsWire
Form 6-K Legend Biotech Corp For: Jun 15
June 15, 2026 8:00 AM - SEC Filing
Legend Biotech reports early trial results for in vivo CAR-T therapy
June 15, 2026 8:00 AM - StreetInsider
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026 8:00 AM - StreetInsider
Legend Biotech reports early clinical trial results for LB2501 therapy
June 14, 2026 8:12 AM - StreetInsider
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026 3:15 AM - StreetInsider
Full Article List
